Enrique María Ocio

27PUBLICATIONS
188CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersGene and molecular therapyAutoimmunityInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Sep 30, 2026
Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.

|Jun 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

|Apr 13, 2026
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.

Enrique M Ocio, Gurdeep Parmar, María-Victoria Mateos

|Mar 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Shaji Kumar, Sundar Jagannath, Katja C Weisel

|Mar 19, 2026
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Irene Dogliotti, Cristina Jiménez, Veronica Peri

|Jan 29, 2026
Immune biomarkers of increased infection risk in multiple myeloma.

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos

Pageof 5

Frequent Collaborators

15 joint publications

Maria-Victoria Mateos

9 joint publications

Jesus San-Miguel

8 joint publications

Noemi Puig

7 joint publications

Albert Oriol